trial

A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia

NCTId NCT07396870
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Not Yet Recruiting
Enrollment 160 (estimated)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2027-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Not Yet Recruiting
Enrollment
160 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2026-03-31
Primary completion
2027-12-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
LY03020

Sponsors

Luye Pharma Group Ltd.Lead Sponsor

Sites

1 total
Beijing, China

Linked catalysts

1
A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psycho — primary completion2027-12-31

Facts & assertions

4 sourced
Enrollment
160
Phase
PHASE2
Primary Completion Date
2027-12-31
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
LY03020
drug
lead_sponsor
Luye Pharma Group Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication